<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DB1F3731-FE91-49D8-9CF1-6A9452125A35"><gtr:id>DB1F3731-FE91-49D8-9CF1-6A9452125A35</gtr:id><gtr:firstName>S</gtr:firstName><gtr:surname>Moss</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F44B551D-A6E2-4B97-85F2-BB258F0BF0C7"><gtr:id>F44B551D-A6E2-4B97-85F2-BB258F0BF0C7</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Scholefield</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/10581911-9C4A-4FB9-8328-236635EF60D9"><gtr:id>10581911-9C4A-4FB9-8328-236635EF60D9</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Whynes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9826520"><gtr:id>2C4B8ADD-80F0-470E-B4D7-D5F6164D7C2B</gtr:id><gtr:title>Long term follow up Nottingham Screening Study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9826520</gtr:grantReference><gtr:abstractText>Colorectal cancer accounts for around 20,000 deaths per annum in the UK and 60,000 in the United States. Despite impovements in medical care the mortality of this disease has remained largely unchanged over the last ten years (overal 5 year survival reamins 40%). However colorectal cancer is a disease where survival can be improved by early detection of adenomatous polyps and early cacners before they become smyptomatic. A significant reduction in mortality from colorectal cancer has been identified in five randomised trials, the largest of which is the Nottingham study.
Detection and removal of adenomatous polyps at colonoscopy should lead to a reduction in the incidence of colorectal cancer. This has so far only been shown in one trial and occurred after 18 years of follow up. Unfortunately in this trial 40% trial population had been colonoscoped and it is therefore uncertain how much of the incidence reduction was due to screening by FOB testing and how much by colonoscopy. The Nottingham Screening Study provides an unrivalled opportunity to addres this important issue but as yet our data are not mature ( roll out of a national colorectal screening programme using FOB testing seems likely).Our current funding will cease at a median follow up of 14 years. The data so far show that the mortality reduction from colorectal cancer first reproted in 1997 is sustained, and that incidence of colorectal cancer may just be diverging in the screened and control groups. 
We therefore seek a further five years funding to get to 19 years follow up.</gtr:abstractText><gtr:technicalSummary>The Nottingham Screning Study is a population based randomised contolled trial of faecal occult blood (FOB)testing in a population of 152,000. This is the largest screening trial for colorectal cancer in the workd and has shown that a significant sustainable reduction in disease specific mortality of can be achieved by FOB screening This application will investigate the long term costs and benefits of this screening programme, with particular reference to the effect on colorectal cancer incidence.
By 2004 the Nottingham Screening Study cohort will have accrued 14 year median follow up. The only study to show a significant reduction in colorectal cancer incidence following screening, did so after a median of 18 years follow up. 
Furthermore follow up of the Nottingham cohort can provide valuable data to inform decisions in the national roll out of colorectal screening which has been announced (and likely to be FOB based). The Nottingham Screening Study database also provides an opportunity to model the effects of roll out for other new screening technologies.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>406950</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Bowels Cancer Screening Programme Advisory Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>1B9CE118-3541-4103-BF1F-287E0FC15210</gtr:id><gtr:impact>Assisting in developing screening policy</gtr:impact><gtr:outcomeId>DACA34EBE16</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G9826520</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5C2ACE0A-A29E-4DCC-9F5A-B00BFAB172B9</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.4  Population screening</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>